Antares Pharma to Present at the Jefferies 2016 Healthcare Conference
June 01 2016 - 9:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at
4:30 p.m. Eastern Time.
A live webcast of the presentation will be
available via the webcast tab under the Investor Information page
of the Antares website, www.antarespharma.com. A replay of the
webcast will also be archived on Antares’ website for 90 days
following the presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and has recently received a therapeutically
equivalent approval from the U.S. Food and Drug Administration for
VIBEX® Sumatriptan USP for the acute treatment of migraine and
cluster headache. The Company's technology platforms include
VIBEX® disposable auto injectors, disposable multi-use pen
injectors and reusable needle-free injectors. Antares Pharma has a
multi-product deal with Teva Pharmaceutical Industries, Ltd. that
includes VIBEX® epinephrine, exenatide multi-dose pen, and
teriparatide multi-dose pen. Our reusable needle-free
injector for use with human growth hormone (hGH) is sold worldwide
by Ferring B.V. The Company is also working with AMAG
Pharmaceuticals on a subcutaneous method of administering Makena, a
progesterone product indicated for use in lowering the risk of
pre-term birth.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to certain risks and
uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences
include, but are not limited to: the timing and results of the
phase 3 studies for QuickShot® Testosterone (QS T) and acceptance
of the data by the U.S. Food and Drug Administration (“FDA”); the
Company’s ability to successfully complete a New Drug Application
(“NDA”) for QS T and submit to the FDA and approval of the same by
the FDA; Teva’s ability to adequately and timely respond to the
Complete Response Letter received from the FDA for the VIBEX®
epinephrine pen Abbreviated New Drug Application (“ANDA”) and
approval by the FDA of the same, the timing and therapeutic
equivalence rating thereof, and any future purchase orders and
revenue pre or post FDA approval; the timing of the launch of
VIBEX® Sumatriptan Injection USP and the amount of revenue from the
same; the outcome of the pending patent litigation between Teva
Pharmaceutical Industries, Ltd. (Teva) and Eli Lilly and Company
regarding the Teriparatide multi-dose pen; the timing and approval,
if any, by the FDA of Teva’s ANDA for the Teriparatide multi-dose
pen and any future revenue resulting therefrom; the outcome of the
pending patent litigation between Teva and AstraZeneca regarding
the Exenatide multi-dose pen; FDA action with respect to Teva’s
ANDA filed for the Exenatide pen and future revenue from the same;
continued growth of prescriptions and sales of OTREXUP™; the timing
and results of the development project with AMAG Pharmaceuticals
for an auto injector for Makena; the timing and results of research
projects, clinical trials, and product candidates in development;
actions by the FDA or other regulatory agencies with the respect to
the Company’s products or product candidates of its partners;
continued growth in product, development, licensing and royalty
revenue; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and othsoer factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2015, and in
the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking
statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of this press
release, except as required by law.
Contact:
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024